Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products
Rx-360 has released a summary regarding Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products.
FDA recently issued the final guidance "Allowable Excess Volume and Labeled Vial Fill SIze in Injectable Drug and Biological Products". This guidance clarifies the FDA regulatory requirements and recommendations pertaining to allowable excess volume in injectable vials and describes when justification is needed for a proposed excess volume in these injectable drug products. This guidance also discusses the importance of appropriate fill volumes for injectable drug products and recommends that labeled vial fill sizes be appropriate for the intended use and dosing of the drug product.
The guidance addresses withdrawable volume and labeled vial fill size for injectable drug products that are packaged in vials and ampules, including products that require reconstitution. It does not address injectable drug products in other packaging types (e.g., prefilled syringes, intravenous infusino bags) or noninjectable products. The recommendations in the guidance apply to NDAs, ANDAs, BLAs, and supplements or other changes to these applications for new packaging or other changes that may affect the fill volume. Note that the guidance does not specifically address either legacy products or variable dosing from single-use vials.
The guidance states that for all application types, the applicant should communicate with FDA early in the drug development process about the vial size and unique excess volume concerns. The guidance also recommends communicating with FDA as outlined in existing recommendations related to communication with sponsors/applicants, including the Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA.
The guidance also states that the drug product's vial fill size should be appropriate for the labeled use and dosing of the product. When deciding what is appropriate, the following should be considered:
• Single-dose vials should not contain a significant volume beyond what would be considered a usual or maximum dose for the expected use of the drug product. Note that the guidance indicates that a specific quantitative volume of remaining drug product considered 'significant' cannot be specified, volumes remaining that could provide a second dose, or would encourage pooling for a second dose, would be considered excessive.
• Consumers and/or health care providers should not be routinely required to use more than one vial to administer a typical single dose of the drug product.
• Multiple-dose vials should contain no more than 30 mL of drug product except under specific circumstances.
To view or download the FDA Guidance, click here.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance